Krahasoni metodat

	cDLQI (Children's DLQI)	POEM (Matja e Ekzemës e Orientuar nga Pacienti)	Skindex-29 (Instrumenti i Cilësisë së Jetës për Sëmundjet e Lëkurës)
Fusha	Dermatologji	Dermatologji	Dermatologji
Familja	Process / pipeline	Process / pipeline	Process / pipeline
Viti i origjinës	1995	2004	1997
Krijuesi	Lewis-Jones MS, Finlay AY	Charman CR, Venn AJ, Williams HC	Chren MM, Lasek RJ
Lloji	Self-report (parent or child proxy)	Self-report	Self-report
Burimi themelues	Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (cDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942-949.	Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol. 2004;140(12):1513-1519.	Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1997;107(5):707-713.
Emërtime të tjera	cDLQI, Pediatric DLQI	POEM Score	Skindex, Skindex-QoL
Të lidhura	3	2	1
Përmbledhja	The Children's Dermatology Life Quality Index (cDLQI) is a pediatric-adapted version of the adult DLQI, measuring the impact of skin disease on quality of life in children and adolescents aged 4–16 years. Developed by Lewis-Jones and Finlay in 1995, it uses child-friendly language and addresses domains relevant to childhood (school, leisure, friendships, clothing) rather than work and adult relationships. cDLQI is the standard quality-of-life measure in pediatric dermatology trials and clinical practice.	The POEM is a brief, patient-administered severity measure for atopic dermatitis that focuses on frequency of symptoms experienced over the past week. Developed by Charman, Venn, and Williams in 2004, it emphasizes the patient's lived experience rather than clinician observation, making it practical for routine clinical practice and remote monitoring. POEM is increasingly used alongside objective measures in clinical trials and outpatient care.	Skindex-29 is a validated, patient-centered quality-of-life measure specifically designed to assess the impact of any skin disease on patients' symptoms, emotions, and functioning. Developed by Chren, Lasek, and colleagues in 1997, it captures the multidimensional burden of dermatological conditions beyond clinical severity. Skindex-29 is widely used in clinical trials, observational studies, and dermatology practice to ensure that treatment efficacy encompasses quality-of-life outcomes.